← Back to Search

Procedure

CESM for Breast Abnormality

N/A

Waitlist Available

Led By Maxine Jochelson, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Women presenting for mammographic evaluation of an undiagnosed palpable mass found either by self-examination and/or examination by referring physician

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing whether adding dye to veins during a mammogram makes it easier to identify the cause of a lump.

Who is the study for?

This trial is for women who have found a lump in their breast through self-examination or by their doctor, and need a mammogram to figure out what it is. It's not suitable for those who already have a diagnosed breast condition.Check my eligibility

What is being tested?

The study tests Contrast Enhanced Spectral Mammography (CESM), which uses dye injected into the arm to see if it can better identify the cause of breast lumps compared to regular mammograms alone.See study design

What are the potential side effects?

Possible side effects include reactions to the contrast dye similar to those sometimes experienced during CT scans, such as allergic reactions, nausea, or warmth/flushing feeling where the dye is injected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I found a lump in my breast through self-check or my doctor found it.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

positive predictive value

Trial Design

1Treatment groups

Experimental Treatment

Group I: Contrast Enhanced Spectral MammographyExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,933 Previous Clinical Trials

585,373 Total Patients Enrolled

Maxine Jochelson, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

4 Previous Clinical Trials

1,098 Total Patients Enrolled

Media Library

Contrast Enhanced Spectral Mammography (CESM) (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT02406274 — N/A

Breast Abnormality Research Study Groups: Contrast Enhanced Spectral Mammography

Breast Abnormality Clinical Trial 2023: Contrast Enhanced Spectral Mammography (CESM) Highlights & Side Effects. Trial Name: NCT02406274 — N/A

Contrast Enhanced Spectral Mammography (CESM) (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02406274 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still participant vacancies in this research?

"According to clinicaltrials.gov, this research study does not presently have any openings for participants; the trial first appeared on March 1st 2015 and was last changed on June 10th 2022. Nonetheless, 115 other trials are actively accepting enrollees at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities

2015. "Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02406274.